GLP-1 / GIP Agonists
Retatrutide 20mg
A triple agonist targeting GLP-1, GIP, and glucagon receptors for metabolic research
Form
Lyophilized Powder
Quantity
20mg per vial
Purity
>99% (HPLC)
Sequence
Triple agonist
MW
5,800 g/mol
Storage
-20°C (lyophilized)
Batch Verification
Purity (HPLC)
>99%
Batch ID
VX-RETA20-001
MW Confirmed
LC-MS
Endotoxin
<0.1 EU/mg
Independently verified by Janoshik: HPLC Purity + LC-MS Identity + LAL Endotoxin
Research Applications
Retatrutide is a 16-amino-acid triple agonist targeting GLP-1, GIP, and glucagon receptors for metabolic research
Research indicates Retatrutide activates GLP-1, GIP, and glucagon pathways. Studies explore energy expenditure, substrate utilization, and metabolic optimization.
Research Use Only
This product is intended for laboratory research use only. Not for human consumption or clinical use. Not FDA approved for diagnostic or therapeutic purposes.
This product is intended for laboratory research use only. Not for human consumption or clinical use. Not FDA approved for diagnostic or therapeutic purposes.